Aims: To evaluate the cost of illness from hypertension for the Italian National Health System (NHS). Methods and Results: A prospective analysis was carried out on clinical and economic data recorded in the general practitioners' (GPs) database. Twenty-one GPs working in the Ravenna area in Italy took part in the project on a voluntary basis. The study included 1047 hypertensive patients enrolled between 1 June and 31 December 1997 and continued for 365 days from the date of enrolment. The following costs were calculated: antihypertensive drugs, laboratory tests and instrumental procedures, GP visits for blood pressure control, specialist visits, casualty visits, hospitalisation due to cardiovascular problems. In the whole sample, the most
Introduction
It is widely recognised that essential hypertension is the most common chronic disease that can be effectively treated. Although morbidity and mortality associated with high blood pressure are higher among individuals with the most severe hypertension, there is an important life-saving potential and reduction of end organ damage, if patients with mild and moderate hypertension receive early diagnosis and appropriate treatment. 1 This preventive approach renders the treatment of hypertension a good example of how the direct cost could be balanced against long-term benefits. 2 Nevertheless, there are few published papers on the cost of illness from hypertension [3] [4] [5] and none of them concerning the Italian National Health System (NHS), which should be particularly interested in a longitudinal overview of the cardiovascular problem as it is the public service which is responsible for prevention, the treatment of acute episodes and their outcomes.
As most of hypertension care is given in general practice, 6 a study based on general practitioners' (GPs) medical records in routine primary care offers results that are highly relevant not only to the GPs themselves, but also to the health purchasers. The GPs are the key decision makers as regards medical care in the Italian NHS.
Against this background, we planned a prospective open-ended global outcomes study, called 'the PANDORA project', whose aim was to develop a computer-assisted information system to improve the appropriateness and effectiveness of hypertension management in primary care, and to organise an electronic database to be used in clinical and economic evaluations. The architecture of this project and the feasibility study performed in 1996-1997 was published recently. 7 This paper describes the results of a cost of illness study, performed on the first 1000 patients followed for 1 year.
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Subjects and methods
Twenty-one GPs out of 330 working in the Ravenna area in Italy took part in the project on a voluntary basis. They were a representative sample of the GPs working in Ravenna for age (42.6 ± 3.7 vs 45.7 ± 8.1 years, P = NS) and took care of 8.5% of hypertensive patients living in the Ravenna area. All the GPs who worked single-handed were supplied with a personal computer, which was connected to a remote server via modem, a printer, an automatic blood pressure device (Dinamap 1846SX, Critikon, Tampa, FL, USA), and a dedicated software called So.Ge.Pa ® . The remote server was also linked to the Ravenna Health Service databases (patient, GP, hospital and emergency room visits, and mortality records). Data related to the management of hypertensive patients and included in our cost of illness analysis are listed in Table 1 . Data were gathered and stored either by the GPs themselves or by links with the Health Service databases as previously reported. 7 Data on adverse drug reactions were also collected by the GPs.
Since data entry time lasted 20-25 min for the enrolment visit and about 10 min for each check-up, GPs were invited to recruit at random two hypertensive patients per week. This was done to allow GPs to run the project during the usual surgery hours and to ensure that the results gave a true picture of the management of hypertension in clinical practice.
The enrolment was performed between 1 June and 31 December 1997. Patients of both sexes, aged between 20 and 89 years were enrolled. Each patient was observed for 365 days, from the date of enrolment. To assess to what extent the patients enrolled in the study were representative of the group of patients treated with antihypertensive drugs, we also took into account how many received treatment during the period considered. Each blood pressure value represents the mean of three measurements taken after 5 min of rest in the sitting position. Hypertension was defined as blood pressure higher or equal to 140/90 mm Hg for at least one of the two values or the administration of antihypertensive therapy. Hypertensive patients were classified as 10 Only antihypertensive drugs were considered in the analysis: ie, code C02 antiadrenergic drugs, C03 diuretics, C07 betablockers, C08 calcium channel blockers, C09 angiotensin converting enzyme (ACE) inhibitors and angiotensin II antagonists, were included, according to the World Health Organisation -Anatomical Therapeutic Classification (WHO-ATC). The cost of instrumental and laboratory tests was defined according to the tariffs applied by the Emilia Romagna Region (Table 2) .
Each hospital admission was collected from the hospital database and classified according to the Diagnosis Related Group (DRG) system, currently adopted for hospital reimbursement, in Italy. The Emilia Romagna tariff was applied, ie, 3933 000 ITL per DRG point. Hospital admissions were included only if coded as admissions for cardiovascular reasons (ICD 9 codes 401-405 hypertension, 410 acute myocardial infarction, 411-414 coronary heart disease, 428-429 heart failure, 430-438 brain circulatory diseases), following the WHO ICD-9 classification.
Emergency room visits were defined as visits at the Casualty department, not followed by hospital admission. The tariff in Ravenna hospitals was 120 000 ITL. GPs and specialist visits were estimated respectively as 25 000 and 32 000 ITL according to the tariffs published in the outpatient price list. 11 GP's visits were included in the economic analysis only if blood pressure measure was measured and recorded. All statistical analyses were performed using SPSS-Windows (version 9.0). Results are reported as mean value ± standard deviation or range. The parametric Student's t-test, the non-parametric KruskalWallis test, the Kolmogorov-Smirnov for two samples test and analysis of variance (ANOVA) with the Bonferroni correction were used where appropriate. A P value Ͻ0.05 was regarded as statistically significant.
Results
From 1 June to 31 December 1997 1076 patients were enrolled and a further 3469 patients were treated with antihypertensive drugs (together these represent 13.8% of the patients in the care of the 21 GPs). Twenty-nine patients (17 who died and 12 who changed either their address or the GP) were excluded from the analysis. Among the 1047 patients who completed the follow-up period, 78 hypertensive patients (37 males and 41 females, aged between 25 and 87 years) were classified as incident and 969 hypertensive patients (443 males and 526 females, aged between 23 and 88 years) were defined as prevalent. During the same period, the GPs treated a total of 3828 patients for hypertension, 359 defined as incident and 3469 as prevalent. Among the incident patients, those enrolled were generally younger than those treated in general (55.5 ± 14.1 vs 63.6 ± 15.9 years, P Ͻ 0.001) and treated with a lower number of antihypertensive drug classes (1.3 ± 0.6 vs 1.5 ± 0.7 classes, P Ͻ 0.05) while there were no significant differences as regards sex. Amongst the prevalent patients, those enrolled were younger than those generally treated (63.6 ± 10.8 vs 69.8 ± 11.8 years, P Ͻ 0.001) with a larger number of females (M/F ratio 0.8 vs 0.7, P Ͻ 0.05) and treated with a larger number of antihypertensive drug classes (1.7 ± 0.8 vs 1.6 ± 0.8 classes, P Ͻ 0.01).
The clinical features of the patients who completed the follow-up are reported in Table 3 . On enrolment, 327 patients (33.7%) had normal blood pressure, while at the end of the follow-up those with normal blood pressure were 382 (39.4%). The arterial blood pressure showed a mean decrease of 3.5 mm Hg (from 147.8 ± 20.4 to 144.3 ± 20.8 mm Hg, P Ͻ 0.01), diastolic blood pressure showed a mean decrease of 1.8 mm Hg (from 80.3 ± 9.9 to 78.5 ± 10 mm Hg, P Ͻ 0.05), while there were no variations in heart rate (from 70.8 ± 12.1 to 70.8 ± 12 beats per min). None of the incident patients were taking any antihypertensive drugs on enrolment, at the end of the follow-up 70 were taking 1 drug, seven 2 drugs and one 3 drugs. Amongst the prevalent patients, the majority were taking just one drug at the start and at the end of the administration period ( Table 4) . The drugs most frequently used for the incident and for the prevalent patients were the ACE-inhibitors, followed by calcium-antagonists, beta-blockers and diuretics.
During follow-up, two of the incident patients were admitted to hospital once, two twice and one 5 times. The reasons were acute myocardial infarction (n = 2), coronary heart disease (n = 7) and heart failure (n = 2).
Amongst the prevalent patients, 17 were admitted to hospital once, eight twice, one 3 times and one 6 times. The reasons were: investigation of secondary hypertension (n = 4), acute myocardial infarction (n = 2), coronary heart disease (n = 11) and heart failure (n = 11), brain circulatory disease (n = 14). No patients were referred to the hospital for adverse antihypertensive drug reactions. The total cost is shown in Table 5 .
All patients were prescribed antihypertensive drugs and all of them visited their GP for blood . Specialist consultations and tests accounted for less than 5% of total costs. The greatest expense for antihypertensive drugs was due to the products with effects on the renin-angiotensin system ( Table 6 ). The average cost, per patient per year, of each resource used, as well as the total (average) cost calculated in the incident and prevalent groups is reported in Table 7 . Both the incident patients and the prevalent patients were analysed, separating those admitted to hospital for cardiovascular problems from the others. Analysis of variance (ANOVA) revealed that the four groups of patients were significantly different as regards the cost of drugs, the cost of GP visits, cost of access to Casualty Depart- ments, the cost of admission to hospital and the average annual cost. When the Bonferroni correction was applied, the cost of drugs was found to be significantly higher in the prevalent patients, whether hospitalised or outpatients, than in the incident outpatients. The cost of GP visits was significantly higher in the prevalent patients, whether hospitalised or outpatients, than in the incident outpatients. The prevalent hospitalised patients had a significantly higher cost for access to the Casualty Department than the prevalent and incident outpatients. The cost of the GP visits was significantly higher in the prevalent outpatients than in the prevalent hospitalised patients, and, in the latter as compared to the incident outpatients. The cost of hospitalisation was significantly higher for the incident patients than for the prevalent patients. There was no significantly difference in the average annual cost for prevalent and incident outpatients, while all the other comparisons gave significantly different results.
In the prevalent patients, we also evaluated the role of patient age on cost, as illustrated in Table 8 . Among patients aged 65 years or less, drugs represented the most significant resource consumed (53.8% of total cost), whilst drug therapy and hospital admissions were almost comparable in terms of absolute value and percentage share in patients over 65 years. The mean total cost was significantly higher in older patients (796 452 ± 1248 791 vs 1171 410 ± 2526 622 ITL respectively, P Ͻ 0.001). The cost of antihypertensive therapy, the cost of specialist visits, the cost of hospitalisation and the cost of tests were significantly different (P Ͻ 0.05) between the two groups, while the cost of GP visits and casualty visits did not contribute to the difference. 
Discussion
Hypertension represents an important area of concern for economic evaluations because of the broad range of issues involved for the individual and society. It is one of the most expensive diseases to treat, as it produces health care expenses 80% greater than those generated by normotensive subjects. 12 Furthermore, it is inadequately treated in a large number of patients, 13 thus contributing largely to major organ damages, especially in subjects with higher blood pressure values. Such complications add considerable costs to the overall cost of care: improvements in the management of hypertension should reduce the incidence of these complications and therefore improve cost control. Moreover, hypertension is frequently associated with other comorbidities which themselves require medical management.
Assuming that this condition could be treated more effectively and more cost-effectively in an integrated managed-care system, rather than by individual GPs working in isolation, we implemented the PANDORA clinical information system in order to obtain a good source of data to measure transition probabilities and health care costs that reflect real everyday practice. Data in this study are observational, that is, they represent what actually occurs in the real health care practice in Ravenna. As such, these data offer complementary information to that obtained from clinical trials that are conducted under controlled and restricted circumstances. The identification of the patients enrolled in the study as compared to those treated for hypertension made it possible to obtain a precise picture of the group of patients followed by us. Both the patients in the prevalent and those in the incident groups enrolled were younger than the general population treated, but this difference, which will be eliminated with the continuation of the study, does not alter the clinical and economic results. As the PANDORA project should be a permanent study, the ultimate aim is to include in the project all hypertensive patients.
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From a clinical point of view, the PANDORA project in its first year of life made it possible to set up a database which could identify the general patient risk and therefore be useful to the GP as an indication of when to change from the treatment of a single risk factor to the overall management of the cardiovascular risk. On this point we consider as significant the modest improvement in the percentage of normotensive patients (+5.7%), obtained with an educational feedback in a bimonthly meeting during which the GPs taking part in the project could examine and discuss the data.
The main objective was to obtain a sufficient sample number to facilitate increasingly more precise analyses, differentiated from a clinical point of view, thus creating an information system to be used by those responsible for individual clinical disease management (GPs and specialists) as well as those responsible for the general strategic disease management (local public health managers and politicians).
To calculate the cost of hypertension, we applied the cost of illness approach. 8, 9 This is a well established and straightforward approach where three major methodological issues are addressed: the definition of which costs to include and the cost data collection method; the choice between the topdown (average cost obtained by dividing the total cost by the number of subjects) and bottom-up (average cost calculated on the basis of the cost for each individual subject) methods, in order to assess these costs; the decision to collect data on an incidence based rather than prevalence-based epidemiological approach.
Besides the identification of intermediate and hard outcomes reached by mutual consent among NHS executives, project co-ordinators, GPs and cardiovascular specialists, we decided to focus on direct costs and to put a value on the resources used for detection, treatment and long-term care of hypertensive patients. One of the major problems in the economic assessment of the cost of hypertension is that of separating the elements associated with the treatment of symptoms from those associated with cardiovascular disease in general (ie, acute episodes vs long term care). For this reason, we choose to calculate the cost of hypertension using the bottom-up method on the basis of a database generated by GPs.
As a simple and useful result of this approach, the description and presentation of the separate components of direct cost in current practice was presented, whilst most of the discussion about the costs of the health care management of hypertension only focus on the cost of medications. Our results confirmed by the data for the entire population for Ravenna, 14 show how ACE-inhibitors, amongst the most expensive drugs, are the most widely prescribed, without there being any clear reason for this at the moment. It is obvious that the cost of different drugs used to treat hypertension may differ significantly, therefore affecting the total cost for each patient, but there are other aspects of care that must be considered and these may be even more important in determining total costs. Moreover, in our study we also had the possibility of identifying the cost of each single patient, so that the consumption of resources could be related to patient compliance, which is crucial for efficacy.
Finally, our study estimates the costs attributable to hypertension both from an incidence-based and prevalence-based perspective. The latter approach identifies the costs incurred during a given year by subjects with high blood pressure. 9 However, this approach does not quantify the long-term consequences of a condition such as hypertension. Consequently, an incidence-based cost of illness assessment, which estimates the lifetime costs of cases diagnosed in a given year, would be more appropriate. 9 The long-term follow-up of incident hypertensive patients, one of the major aims of the PANDORA project, will allow us to demonstrate whether the implementation of simple and easy-to-follow guidelines (defining persistent high blood pressure, presence of other cardiovascular risk factors and suggesting the most effective management techniques to be implemented), can reduce the economic cost and improve the clinical outcomes of the disorder.
Since an important issue concerning study design when testing an economic hypothesis is the identification of an appropriate sample size, as well as an adequate length of follow-up, our study should be considered as preliminary, nevertheless we believe that it represents a useful step towards the evaluation of the true cost of hypertension.
